Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255202174> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2255202174 endingPage "0" @default.
- W2255202174 startingPage "0" @default.
- W2255202174 abstract "Background: Diabetes mellitus is the most common cause of renal failure, blindness, non- traumatic amputation and neuropathy. Homocysteine, a sulfurated amino acid, has a close correlation with Methionine and Cysteine. The conversion of Methionine to Homocysteine and Cysteine is required coenzymes like vitamin B6, B12 and Folate. The effect of Metformin on serum Homocysteine level by decreasing vitamin B12 level in patients with type 2 diabetes mellitus was described previously. Methods: This is a prospective clinical trail study among patients with type 2 diabetes mellitus in Shiraz. 76 patients were divided into two groups (38 patients in each group). First group treated with Metformin 500-2000 mg/day and the second group treated with Glibenclamide 5-20 mg/day with follow up period of at least 6 months. Hb and MCV were used in follow up to detect megaloblastic anemia, indicator of B12 and folate deficiency. Fasting plasma Homocysteine level Hb A1C and blood sugar were measured in baseline and at 3 and 6 months follow up periods. Results: There was no significant difference between age, sex, weight, height and BMI and baseline serum profile between the two groups. Homocysteine level increased significantly in Metformin group at 3 and 6 months(P=0.003 and 0.001 respectively). Mean plasma homocysteine level after 6 months were 10.98±0.58 μmol/l in Metformin and 10.0± 0.88 μmol/l in Glibenclamide group, with significant difference between the two groups (P=0.001). Conclusion: Metformin increases the plasma Homocysteine level. Metformin will accumulate highly in gastrointestinal wall and cause malabsorption of vitamin B12, therefore we can conclude that the use of Metformin for 6 months can cause vitamin B12 malabsorption and increase in plasma homocysteine level. Increase in plasma homocysteine level was 7.54% in our study that is higher in comparing to the other studies. It can be explained by longer duration of Metformin therapy in our study. Rising in Homocysteine levels may have detrimental effect on vessels that need further study" @default.
- W2255202174 created "2016-06-24" @default.
- W2255202174 creator A5004371970 @default.
- W2255202174 creator A5010132162 @default.
- W2255202174 creator A5043177717 @default.
- W2255202174 creator A5070128756 @default.
- W2255202174 creator A5088292093 @default.
- W2255202174 date "2004-08-15" @default.
- W2255202174 modified "2023-09-27" @default.
- W2255202174 title "COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS GLIBENCLAMIDE TREATED TYPE 2 DM PATIENTS." @default.
- W2255202174 hasPublicationYear "2004" @default.
- W2255202174 type Work @default.
- W2255202174 sameAs 2255202174 @default.
- W2255202174 citedByCount "0" @default.
- W2255202174 crossrefType "journal-article" @default.
- W2255202174 hasAuthorship W2255202174A5004371970 @default.
- W2255202174 hasAuthorship W2255202174A5010132162 @default.
- W2255202174 hasAuthorship W2255202174A5043177717 @default.
- W2255202174 hasAuthorship W2255202174A5070128756 @default.
- W2255202174 hasAuthorship W2255202174A5088292093 @default.
- W2255202174 hasConcept C126322002 @default.
- W2255202174 hasConcept C134018914 @default.
- W2255202174 hasConcept C2777090595 @default.
- W2255202174 hasConcept C2777180221 @default.
- W2255202174 hasConcept C2779750884 @default.
- W2255202174 hasConcept C2779768347 @default.
- W2255202174 hasConcept C2780323712 @default.
- W2255202174 hasConcept C2910068830 @default.
- W2255202174 hasConcept C555293320 @default.
- W2255202174 hasConcept C71924100 @default.
- W2255202174 hasConcept C90924648 @default.
- W2255202174 hasConceptScore W2255202174C126322002 @default.
- W2255202174 hasConceptScore W2255202174C134018914 @default.
- W2255202174 hasConceptScore W2255202174C2777090595 @default.
- W2255202174 hasConceptScore W2255202174C2777180221 @default.
- W2255202174 hasConceptScore W2255202174C2779750884 @default.
- W2255202174 hasConceptScore W2255202174C2779768347 @default.
- W2255202174 hasConceptScore W2255202174C2780323712 @default.
- W2255202174 hasConceptScore W2255202174C2910068830 @default.
- W2255202174 hasConceptScore W2255202174C555293320 @default.
- W2255202174 hasConceptScore W2255202174C71924100 @default.
- W2255202174 hasConceptScore W2255202174C90924648 @default.
- W2255202174 hasIssue "2" @default.
- W2255202174 hasLocation W22552021741 @default.
- W2255202174 hasOpenAccess W2255202174 @default.
- W2255202174 hasPrimaryLocation W22552021741 @default.
- W2255202174 hasRelatedWork W1971172093 @default.
- W2255202174 hasRelatedWork W1988269619 @default.
- W2255202174 hasRelatedWork W2007293299 @default.
- W2255202174 hasRelatedWork W2065693992 @default.
- W2255202174 hasRelatedWork W2092380870 @default.
- W2255202174 hasRelatedWork W2280013044 @default.
- W2255202174 hasRelatedWork W2324163085 @default.
- W2255202174 hasRelatedWork W2349854721 @default.
- W2255202174 hasRelatedWork W2355914272 @default.
- W2255202174 hasRelatedWork W2369954548 @default.
- W2255202174 hasRelatedWork W2370097336 @default.
- W2255202174 hasRelatedWork W2378896524 @default.
- W2255202174 hasRelatedWork W2379934809 @default.
- W2255202174 hasRelatedWork W2403737663 @default.
- W2255202174 hasRelatedWork W2782122531 @default.
- W2255202174 hasRelatedWork W2887130641 @default.
- W2255202174 hasRelatedWork W2980197628 @default.
- W2255202174 hasRelatedWork W3081882915 @default.
- W2255202174 hasRelatedWork W3128907904 @default.
- W2255202174 hasRelatedWork W3197145440 @default.
- W2255202174 hasVolume "4" @default.
- W2255202174 isParatext "false" @default.
- W2255202174 isRetracted "false" @default.
- W2255202174 magId "2255202174" @default.
- W2255202174 workType "article" @default.